This creates a sensation of swelling and leads to a lack of confidence in my balance and walking.

Pomalyst plus Velcade with dexamethasone improves survival outcomes for patients with relapsed/refractory multiple myeloma, according to a phase 3 trial. The treatment combination of Pomalyst ...

A treatment combination that includes Velcade and Rituxan helps improve responses and the safety profile in marginal zone lymphoma, according to a phase 2 trial. Velcade (bortezomib), Rituxan ...

The approval follows results from the RETRIEVE trial, conducted in patients who had previously responded to Velcade but had relapsed. The Takeda Oncology Company with its parent company, Takeda ...

(Reuters) - Takeda Pharmaceutical Co's Velcade reduced the risk of death by 31 percent when used in combination with standard medicines in previously untreated multiple myeloma patients, according to ...